Magnetar Financial LLC Sells 11,720,811 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Magnetar Financial LLC reduced its holdings in Elanco Animal Health by 97.4%, owning only about 311,514 shares valued at $3.27 million after selling over 11.7 million shares.
• Elanco Animal Health's stock received several upgrades from analysts, with ratings ranging from "buy" to "strong-buy" and a price target set at $18.00.
• The company reported earnings of $0.26 per share for the last quarter, exceeding analyst expectations, and its year-over-year revenue increased by 4.8% to $1.24 billion.

Magnetar Financial LLC decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 97.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 311,514 shares of the company's stock after selling 11,720,811 shares during the period. Magnetar Financial LLC owned approximately 0.06% of Elanco Animal Health worth $3,271,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP grew its holdings in shares of Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after buying an additional 2,090 shares during the period. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at $29,000. NBC Securities Inc. acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $40,000. Parallel Advisors LLC grew its holdings in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after buying an additional 1,852 shares during the period. Finally, Versant Capital Management Inc lifted its position in Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after acquiring an additional 1,740 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ELAN shares. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. UBS Group boosted their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target on the stock in a research report on Thursday, July 17th. Finally, Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock traded down $0.05 during trading on Thursday, hitting $17.31. 1,552,554 shares of the stock were exchanged, compared to its average volume of 5,991,083. The stock has a market capitalization of $8.60 billion, a price-to-earnings ratio of 20.11, a price-to-earnings-growth ratio of 3.41 and a beta of 1.62. The company has a fifty day moving average price of $15.81 and a 200-day moving average price of $12.83. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $18.87. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. Elanco Animal Health's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.